Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”

Biomarkers of bone turnover in serum are suggestive of bone dynamics during treatment in multiple myeloma (MM). We evaluated the role of daratumumab on bone remodeling among patients with relapsed/refractory MM in the prospective, open-label, phase 2 study REBUILD. Daratumumab was administered accor...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis-Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Kyriaki Manousou, Sosana Delimpasi, Panagiotis Malandrakis, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios-Athanasios Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
multiple myeloma
daratumumab
bone metabolism
biomarker
clinical trial
Online Access:https://www.mdpi.com/2072-6694/14/11/2768

Internet

https://www.mdpi.com/2072-6694/14/11/2768

Similar Items